Factors affecting circadian variability

被引:10
作者
Giles, TD [1 ]
机构
[1] Louisiana State Univ, Sch Med, New Orleans, LA 70012 USA
关键词
angiotensin II; angiotensin II receptor; blood pressure; cardiovascular disease; circadian rhythm; renin-angiotensin system;
D O I
10.1097/00126097-200005001-00002
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Several unfavorable cardiovascular events show a well-defined pattern in their occurrence throughout the day. Myocardial infarction and ischemia, sudden cardiac death and stroke occur with greater frequency in the morning hours after awakening. Multiple biologic functions such as blood pressure, heart rate, sympathetic neurotransmission, vascular tone, platelet aggregability, and coagulation parameters also show a diurnal variation and appear to contribute to adverse cardiac outcomes. Recent studies have emphasized the importance of 24 h control in decreasing cardiovascular risk. The renin-angiotensin system (RAS), through the important effector peptide, angiotensin II (Ang II), has potent effects on blood pressure, salt and water homeostasis, and target-organ damage. Inhibiting the RAS consequently becomes an important therapeutic avenue for treating hypertension and target-organ damage. Ang II receptor antagonists selectively compete with the binding of Ang II to the Ang II type 1 receptor and, by inhibiting the multiple activities mediated by Ang II at this receptor, may confer cardiovascular benefits additional to that of blood pressure control. Ang II receptor antagonists with an intrinsically long duration of action that produce smooth, sustained antihypertensive activity over the dosing period provide a similar 24 h benefit of Ang II inhibition. Blood Press Monit 5 (suppl 1):S3-S7 (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:S3 / S7
页数:5
相关论文
共 42 条
[1]   ASSOCIATION OF THE RENIN SODIUM PROFILE WITH THE RISK OF MYOCARDIAL-INFARCTION IN PATIENTS WITH HYPERTENSION [J].
ALDERMAN, MH ;
MADHAVAN, S ;
OOI, WL ;
COHEN, H ;
SEALEY, JE ;
LARAGH, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (16) :1098-1104
[2]   Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle [J].
Ambrose, J ;
Pribnow, DG ;
Giraud, FD ;
Perkins, KD ;
Muldoon, L ;
Greenberg, BH .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 33 (03) :433-439
[3]   MAJOR CIRCADIAN FLUCTUATIONS IN FIBRINOLYTIC FACTORS AND POSSIBLE RELEVANCE TO TIME OF ONSET OF MYOCARDIAL-INFARCTION, SUDDEN CARDIAC DEATH AND STROKE [J].
ANDREOTTI, F ;
DAVIES, GJ ;
HACKETT, DR ;
KHAN, MI ;
DEBART, ACW ;
ABER, VR ;
MASERI, A ;
KLUFT, C .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (09) :635-637
[4]   Chronotherapeutics for cardiovascular disease [J].
Anwar, YA ;
White, WB .
DRUGS, 1998, 55 (05) :631-643
[5]   ANTIHYPERTENSIVE THERAPY WITH MK-421 - ANGIOTENSIN-II-RENIN RELATIONSHIPS TO EVALUATE EFFICACY OF CONVERTING ENZYME BLOCKADE [J].
BIOLLAZ, J ;
BRUNNER, HR ;
GAVRAS, I ;
WAEBER, B ;
GAVRAS, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1982, 4 (06) :966-972
[6]   MORNING INCREASE IN PLATELET AGGREGABILITY - ASSOCIATION WITH ASSUMPTION OF THE UPRIGHT POSTURE [J].
BREZINSKI, DA ;
TOFLER, GH ;
MULLER, JE ;
POHJOLASINTONEN, S ;
WILLICH, SN ;
SCHAFER, AI ;
CZEISLER, CA ;
WILLIAMS, GH .
CIRCULATION, 1988, 78 (01) :35-40
[7]   Angiotensin II receptor pharmacology and AT1-receptor blockers [J].
Chung, O ;
Csikós, T ;
Unger, T .
JOURNAL OF HUMAN HYPERTENSION, 1999, 13 (Suppl 1) :S11-S20
[8]   PATHOPHYSIOLOGY OF SILENT-MYOCARDIAL-ISCHEMIA DURING DAILY LIFE - HEMODYNAMIC EVALUATION BY SIMULTANEOUS ELECTROCARDIOGRAPHIC AND BLOOD-PRESSURE MONITORING [J].
DEEDWANIA, PC ;
NELSON, JR .
CIRCULATION, 1990, 82 (04) :1296-1304
[9]  
Dendorfer A, 1998, BASIC RES CARDIOL, V93, P24
[10]   Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal [J].
Dodt, C ;
Breckling, U ;
Derad, I ;
Fehm, HL ;
Born, J .
HYPERTENSION, 1997, 30 (01) :71-76